Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 13
Original Research
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 12,539 | Dovepress* | 11,304+ | 1,774 | 13,078 | |
| PubMed Central* | 1,235 | 445 | 1,680 | ||
| Totals | 12,539 | 2,219 | 14,758 | ||
| *Since 29 June 2017 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 4 | 0 | 0 | 0 | 0 | 4 |
View citations on PubMed Central and Google Scholar